This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571) Precision Medicine (75) Clinical Information and Decision Making (1407) Genomics and Bioinformatics for Clinical Use (35) Precision Medicine and Genetics (48) Innovations and Technology for Cancer Prevention and Screening (147)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54042, first published .
A Predictive Noninvasive Single-Nucleotide Variation–Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study

A Predictive Noninvasive Single-Nucleotide Variation–Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study

A Predictive Noninvasive Single-Nucleotide Variation–Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study

Authors of this article:

Nico Seeger1 Author Orcid Image ;   Stefan Gutknecht2 Author Orcid Image ;   Irin Zschokke3 Author Orcid Image ;   Isabella Fleischmann3 Author Orcid Image ;   Nadja Roth3 Author Orcid Image ;   Jürg Metzger3 Author Orcid Image ;   Markus Weber2 Author Orcid Image ;   Stefan Breitenstein1 Author Orcid Image ;   Lukasz Filip Grochola1 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Safaie N, Idari G, Ghasemi D, Hajiabbasi M, Alivirdiloo V, Masoumi S, Zavvar M, Majidi Z, Faridvand Y. AMPK activation; a potential strategy to mitigate TKI-induced cardiovascular toxicity. Archives of Physiology and Biochemistry 2024:1 View